Atea Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:AVIR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 490.96 M464.67 M439.96 M391.61 M342.96 M Total liabilities 32.44 M25.8 M28.88 M27.19 M27.18 M Total equity 458.52 M438.87 M411.08 M364.42 M315.78 M Total liabilities & shareholders' equities 490.96 M464.67 M439.96 M391.61 M342.96 M Total debt ————— Net debt —————

News

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AVIR) 2026-01-19

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea’s HCV treatment regimen phase 3 results expected mid-2026

Atea Pharmaceuticals: Best-In-Class HCV Cure With Pivotal Readouts In 2026 (NASDAQ:AVIR)

Atea completes enrollment in HCV treatment phase 3 trial

Atea Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2025-11-14

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Cisco, Flutter, Manulife and more set to report earnings Wednesday

Atea’s hepatitis C drug combination shows promising results in modeling study

Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call Presentation (NASDAQ:AVIR)